Pill burden in hypertensive patients treated with single-pill combination therapy - An observational study

Advances in Therapy

Volumn 30, Issue 4, 2013, Pages 406-419

  Hagendorff, Andreas ^a   Freytag, Siegfried ^b   Müller, Alfons ^c   Klebs, Sven ^c  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b KANTAR HEALTH   (United States)

^c Novartis Pharma GmbH   (Germany)

Author keywords

Amlodipine; Cardiology; Combination therapy; Germany; Hydrochlorothiazide; Hypertension; Observational study; Pill burden; Triple therapy; Valsartan

Indexed keywords

AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS VALSARTAN;

ADULT; AGED; ARTICLE; ATTITUDE TO ILLNESS; CLINICAL PRACTICE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; ESSENTIAL HYPERTENSION; FEMALE; GERMANY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT ATTITUDE; PHARMACEUTICAL CARE; PHYSICIAN ATTITUDE; PILL BURDEN; POLYPHARMACY; PROSPECTIVE STUDY; QUESTIONNAIRE;

AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; COST OF ILLNESS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES; VALINE;

EID: 84878020463     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0018-3     Document Type: Article

References (31)

1. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther. 2011;5:325-380.
2. Kearney P, Whelton M, Reynolds K, Muntner P, Whelton P, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365:217-223.
3. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10-17.
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
5. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
6. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004;116(Suppl. 5A):30S-38S.
7. Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
8. Jamerson K, Bakris GL, Dahlöf B, et al; ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16:80-86.
9. Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
10. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794-811.
11. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772-779.
12. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147-1152.
13. Rottlaender D, Scherner M, Schneider T, Erdmann E. [Multimedikation, compliance und zusatzmedikation bei patienten mit kardiovaskulären erkrankungen]. Dtsch Med Wochenschr. 2007;132:139-144. In German.
14. Mancia G, De BG, Dominiczak A, et al; the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension; the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536.
15. Volpe M, Chin D, Paneni F. The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol. 2010;24:9-17.
16. Theobald K, Capan M, Herbold M, Schinzel S, Hundt F. Quality assurance in non-interventional studies. GMS Ger Med Sci. 2009;7:Doc 29.
17. Lüders S, Schrader J, Schmieder RE, Smolka W, Wegscheider K, Bestehorn K. Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial. Eur J Cardiovasc Prev Rehabil. 2010;17:271-279.
18. Qureshi NN, Hatcher J, Chaturvedi N, Jafar TH. Effect of general practitioner education on adherence to antihypertensive drugs: cluster randomized controlled trial. BMJ. 2007;335:1030.
19. Adherence to long-term therapies. Evidence for action. 2003. World Health Organization website. Available at: http://whqlibdoc.who.int/publications/2003/ 9241545992.pdf. Accessed Mar 12 2013.
20. Neutel JM, Smith DHG. Improving patient compliance: a major goal in the management of hypertension. J Clin Hypertens. 2003;5:127-132.
21. Cadieux RJ. Drug interactions in the elderly. How multiple drug use increases risk exponentially. Postgrad Med. 1989;86:179-186.
22. Fux R, Greiner D, Geldmacher M, Mörike K, Gleiter CH. Multiple drug prescribing by general practitioners in a German region: Implications for drug interactions and patient safety. Int J Clin Pharmacol Ther. 2006;44:539-547.
23. Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4:36-41.
24. Jesson B. Minimising the risk of polypharmacy. Nurs Older People. 2011;23:14-20.
25. Wehling M. Guideline-driven polypharmacy in elderly, multimorbid patients is basically flawed: there are almost no guidelines for these patients. J Am Geriatr Soc. 2011;59:376-377.
26. Patterson SM, Hughes C, Kerse N, Cardwell CR, Bradley MC. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2012;5:CD008165.
27. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170:1648-1654.
28. Gokula M, Holmes HM. Tools to reduce polypharmacy. Clin Geriatr Med. 2012;28:323-341.
29. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312:1215-1218.
30. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344-349.
31. Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122:114-120.